A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a...
A group of T2 weighted hyperintensities that disseminate in what is called a “punctate pattern” (PP) may directly precede the appearance of progressive multifocal leukoencephalopathy (PML) lesions,...
A case report of a woman with relapsing-remitting multiple sclerosis (RRMS) who developed shingles while being treated with Tecfidera has raised questions of whether the drug reactivates the...
Secondary health issues are very common in multiple sclerosis (MS) and exerts a significant impact on health-related quality of life (HRQoL), results of two studies published in Neurology indicate....
Three in five people who contest a decision to reject their Personal Independence Payment win on appeal, figures have revealed.
Huge numbers of disabled people are being wrongly denied Personal...
The immune system-suppressing multiple sclerosis (MS) drug Gilenya also has potentially beneficial effects on the nervous system, according to a recent study.
Gilenya is a relatively new medication...
Yoga and aquatic exercise may reduce certain symptoms of multiple sclerosis (MS) such as fatigue, depression and paraesthesia, a new study suggests.
For the study, researchers from University of...
PJSC Pharmsynthez, a pharmaceutical company based in Russia, has announced completed follow-up findings and data analysis from a Phase 2a proof-of-concept clinical trial of its therapeutic vaccine...
Recent studies have shown that Tecfidera decreased certain immune cells, of both B-, and T-cell type in MS patients. Studies have also indicated that this class of drugs affects the signalling...
RedHill Biopharma has announced “encouraging” top-line interim results from its CEASE-MS Phase IIa proof-of-concept (PoC) clinical study evaluating fixed oral doses of RHB-104 in patients treated for...
